RxDoctor Payments Data

Michael Ehrenman, MD

Internal Medicine · Plantation, FLNPI 1679522395

Payments from drug & device makers

$978in general payments, 2019–2025

Across 37 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$284
  • Novartis$226
  • Astellas Pharma US Inc$100
  • GSK$99
  • Sunovion Pharmaceuticals Inc.$76
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$70
  • plus $122 from 4 others

What the payments were for

  • Food & beverage$89391%
  • Education$859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$978 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$17,951
Medicare patients
32
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$72,238
JanuviaSitagliptin Phosphate37$36,270
EliquisApixaban37$32,484
OzempicSemaglutide16$16,540
Arnuity ElliptaFluticasone Furoate35$7,170
Rosuvastatin Calcium316$2,997
Atorvastatin Calcium254$2,144
Labetalol Hcl29$1,908
Levothyroxine Sodium149$1,864
Losartan Potassium209$1,855
Metoprolol Succinate139$1,779
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,433
Amlodipine Besylate361$1,183
Hydrochlorothiazide188$997
Nifedipine ErNifedipine29$989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$32,48437 claims
GSKArnuity Ellipta$99$7,17035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →